Taxanes for adjuvant treatment of early breast cancer (Q24242987)

4

0 references

author name string

Thomas Ferguson

1

0 references

Rosemary Vagg

3

0 references

Anna K Nowak

Cochrane Database of Systematic Reviews

5

0 references

publication date

17 October 2007

0 references

published in

0 references

cites work

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Chemotherapy for metastatic breast cancer-report of a European expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004421.PUB2